

# Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis

NCT06076304

---

Status	RECRUITING
Phase	Phase 4
Sponsor	Daniel Merenstein
Enrollment	3,720 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- years old; AND are experiencing either:
- "persistent" symptoms or signs compatible with ARS or sinus infection lasting for 1-21 days without any evidence of clinical improvement (Symptoms include facial pain or pressure, facial congestion or fullness, nasal obstruction, nasal discharge, no or reduced sense of smell, fever  $\geq 39^{\circ}\text{C}$  or  $102^{\circ}\text{F}$ , headache, bad smelling breath, fatigue, ear pain or pressure, and dental pain); OR
- onset with worsening symptoms or signs characterized by the new onset of fever, headache, or increase in nasal discharge following a typical viral upper respiratory infection (URI) that lasted 5-6 days and were initially improving ("double-sickening").

### Exclusion (12)

- allergy or intolerance to penicillin
- received systemic antibiotic therapy in the past 4 weeks
- prior sinus surgery (cosmetic surgery, such as rhinoplasty, septal deviation, etc. are not exclusionary)
- complications of sinusitis (facial edema (swelling), cellulitis), or orbital, meningeal or cerebral signs)
- health care clinician determined IV (intravenous) antibiotics or hospital admission are required
- ... and 7 more (see full listing online)

## Locations (7 total)

---

University of California, Los Angeles, Los Angeles, California, United States  
Georgetown University Medical Center, Washington D.C., District of Columbia, United States  
MedStar Health Research Institute, Hyattsville, Maryland, United States  
... and 4 more locations